Pfizer Discontinues Its Development Program In Lung Cancer For PF-3512676
Pfizer Inc. announced that it has discontinued its development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy. This includes two Phase 3 clinical trials and two Phase 2 clinical trials.
This entry was posted on Wednesday, June 20th, 2007 at 6:28 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.